原发性胆汁性胆管炎的新治疗范式
本文综述原发性胆汁性胆管炎(PBC)的发病机制与治疗进展。PBC 以慢性淋巴细胞性胆管炎、界面性肝炎、胆管减少、胆汁淤积和进行性胆管纤维化为特征,症状以疲劳、瘙痒、腹痛和干燥复合征为主。一线治疗为熊去氧胆酸,对生化残留胆汁淤积者加用奥贝胆酸;未来可能获批的药物包括 PPAR 通路激动剂(seladelpar、elafibrinor、saroglitazar)及 IBAT 抑制剂(如 linerixibat)等。
要点
- PBC 是自身免疫性疾病,但治疗长期聚焦于胆汁淤积后果。
- 一线治疗为熊去氧胆酸,残留胆汁淤积者加用奥贝胆酸。
- PPAR 激动剂和 IBAT 抑制剂有望改善瘙痒和胆汁淤积。
核心结论
- PBC 治疗领域令人兴奋,治疗目标日益主动和个体化,力求快速实现血清指标正常和生活质量改善并预防终末期肝病。
研究设计与样本
- 本文为综述,检索范围原文未报告。
主要发现
- PBC 以慢性淋巴细胞性胆管炎伴界面性肝炎、胆管减少、胆汁淤积和进行性胆管纤维化为特征。
- PBC 患者常有症状,生活质量负担以疲劳、瘙痒、腹痛和干燥复合征为主。
- 胆管上皮稳态异常参与疾病,胆管细胞衰老、凋亡和碳酸氢盐分泌受损加剧慢性炎症和胆汁酸潴留。
- 未来可能获批的 PBC 治疗包括 PPAR 通路激动剂,如特异性 PPAR-delta 激动剂 seladelpar,以及 elafibrinor 和 saroglitazar(均为更广泛的 PPAR 激动作用)。
- PPAR 激动剂可减轻瘙痒,IBAT 抑制(如 linerixibat)对瘙痒也似有前景。
关键数值与推荐
- 一线治疗为熊去氧胆酸,一种非特异性抗胆汁淤积剂。
- 对生化残留胆汁淤积者,加用奥贝胆酸,一种半合成法尼醇 X 受体激动剂,具有利胆、抗纤维化和抗炎活性。
- 针对肝纤维化,正在评估 NOX 抑制。
- 更早期在研疗法包括影响免疫调节的治疗及其他瘙痒治疗方法(如 MrgprX4 拮抗剂)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Primary biliary cholangitis (PBC) is an archetypal autoimmune disease. Chronic lymphocytic cholangitis is associated with interface hepatitis, ductopenia, cholestasis, and progressive biliary fibrosis. People living with PBC are frequently symptomatic, experiencing a quality-of-life burden dominated by fatigue, itch, abdominal pain, and sicca complex. Although the female predominance, specific serum autoantibodies, immune-mediated cellular injury, as well as genetic (HLA and non-HLA) risk factors, identify PBC as autoimmune, to date treatment has focused on cholestatic consequences. Biliary epithelial homeostasis is abnormal and contributes to disease. The impact of cholangiocyte senescence, apoptosis, and impaired bicarbonate secretion enhances chronic inflammation and bile acid retention. First-line therapy is a non-specific anti-cholestatic agent, ursodeoxycholic acid. For those with residual cholestasis biochemically, obeticholic acid is introduced, and this semisynthetic farnesoid X receptor agonist adds choleretic, anti-fibrotic, and anti-inflammatory activity. Future PBC licensed therapy will likely include peroxisome proliferator activated receptor (PPAR) pathway agonists, including specific PPAR-delta agonism (seladelpar), as well as elafibrinor and saroglitazar (both with broader PPAR agonism). These agents dovetail the clinical and trial experience for off-label bezafibrate and fenofibrate use. Symptom management is essential, and encouragingly, PPAR agonists reduce itch; IBAT inhibition (eg, linerixibat) also appears promising for pruritus. For those where liver fibrosis is the target, NOX inhibition is being evaluated. Earlier stage therapies in development include therapy to impact immunoregulation in patients, as well other approaches to treating pruritus (eg, antagonists of MrgprX4). Collectively the PBC therapeutic landscape is exciting. Therapy goals are increasingly proactive and individualized and aspire to rapidly achieve normal serum tests and quality of life with prevention of end-stage liver disease.
引用
- Levy C, Manns M, Hirschfield G, et al. New Treatment Paradigms in Primary Biliary Cholangitis. Clin Gastroenterol Hepatol. 2023. PMID: 36809835. doi:10.1016/j.cgh.2023.02.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。